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BONE FORMATION FOLLOWING 4-POINT-BENDING IN THE RAT 
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School of Biomedical Sciences, The University of Queensland, 
Brisbane Qld Australia 4072 
 
ABSTRACT 
 
 Fracture healing is retarded in the presence of cyclooxygenase-2 (COX-2) inhibitors, 
demonstrating an important role of COX-2 in trauma-induced woven bone adaptation. The aim of 
this experiment was to determine the influence of COX-2 inhibition on the remodeling and 
consolidation of non-traumatic woven bone produced by mechanical loading. A periosteal woven 
bone callus was initiated in the right tibia of female Wistar rats following a single bout of four-point-
bending, applied as a haversine wave for 300 cycles at a frequency of 2Hz and a magnitude of 65N. 
Daily injections of Vehicle (VEH: polyethyleneglycol) or the COX-2 inhibitor, DFU (2.0 mg.kg-1 and 
0.02mg.kg-1 i.p.), commenced 7 days postloading, and tibiae were examined 2, 3, 4 and 5 weeks 
postloading. Tibiae were dissected, embedded in polymethylmethacrylate and sectioned for 
histomorphometric analysis of periosteal woven bone. No significant difference in peak woven bone 
area was observed between DFU-treated and VEH rats. But treatment with DFU resulted in a 
temporal defect in woven bone formation, where the achievement of peak woven bone area was 
delayed by one week. Woven bone remodeling was observed in DFU-treated rats at 21 days post-
loading, demonstrating that remodeling of the periosteal callus is not prevented in the presence of a 
COX-2 inhibitor in the rat. We conclude that COX-2 inhibition does not significantly disrupt the 
mechanism of woven bone remodeling, but alters its timing.  
 
Keywords: woven bone; cyclooxygenase isoforms; bone remodeling; periosteal callus; 4-point-
bending. 
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INTRODUCTION 
 
Cyclooxygenase-2 (COX-2) plays an important role in the adaptation of bone to changes in the 
mechanical environment. Bone mechanotransduction is associated with elevated levels of COX-2 
expression, leading to an increased production of prostaglandins and a modulation in bone cell 
activity [1-3]. Whilst COX-2 is not required for normal fetal osteogenesis and bone development [4], 
adaptive bone processes such as fracture healing and loading-induced bone formation do in fact 
demonstrate COX-2-dependency [5-7]. Few studies however have attempted to evaluate the function 
of COX-2 during loading-induced bone remodeling in vivo.  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the cyclooxygenases and are widely 
used today to treat pain and inflammation. Negative effects of NSAIDs on fracture healing are well 
known, with many animal models showing delayed fracture repair, failed bony union and reduced 
bony ingrowth with NSAID treatment [5, 8-14]. Although only few prospective studies are reported 
[15], it is suggested that patients should temporarily avoid or discontinue use of NSAIDs during any 
period of bone repair or following bone trauma [16-20]. However the importance of COX-2 in bone 
healing and in loading-induced bone remodeling, uncomplicated by endochondral ossification, still 
remains uncertain. Severe defects in bone healing have been associated with the inhibition of COX-2 
[5, 6, 21, 22], but this is not universal, with some studies concluding that COX-1 may be more 
important in bone repair [11, 12]. This reinforces a need for further exploration into the role of COX-
2 in woven bone dynamics.  
 
Osteoblastogenesis is potentiated in the presence of COX-2 expression [6]. Therefore the 
abnormal endochondral and intramembranous ossification associated with COX-2 knockout mice, 
may develop through defective recruitment and differentiation of mesenchymal stem cells, retarded 
mineralization and/or reduced remodeling of the fracture callus. Forwood [7] demonstrated that 
COX-2 is not necessary for woven bone formation following 4-point-loading in the rat tibia. That is, 
woven bone modeling does not depend on the expression of COX-2. The role of COX-2 in woven 
bone remodeling during the consolidation phase however, is still unknown. 
 
 The aim of this project was to use a model of mechanically-induced woven bone formation to 
evaluate the effect of a specific COX-2 inhibitor on the remodeling and consolidation of a woven 
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bone callus. We hypothesized that COX-2 inhibition would retard the remodeling of woven bone and 
disrupt callus consolidation. 
 
MATERIALS AND METHODS 
Four-Point-Bending of the Rat Tibia 
One hundred and four female Wistar rats aged 20 (± 2) weeks (298 ± 30.5g) received a single 
bout of 4-point-bending of the right tibia in vivo. The 4-point-bending model allows the investigation 
of the role of COX-2 on activated woven bone surfaces independent of cartilage formation. Loading 
was set at a frequency of 2Hz and a magnitude of 65N for 300 cycles as haversine waves. The 
loading magnitude was chosen because it is known to induce woven bone formation at the periosteal 
surface [23]. The specific 4-point-loading apparatus was designed by Forwood et al. [24] as a 
modified version of the model developed by Turner et al. [25]. The University of Queensland Animal 
Ethics Committee approved all experiments. 
 
Housing 
 After loading, the rats were housed in pairs and were free to return to normal ambulatory 
activity. That is, until euthanasia, the tibia received natural loading patterns after the single 
application of 4-point-bending. All rats had access to standard rat pellets and water ad libitum. The 
temperature was maintained between 18˚C and 23˚C and a diurnal light control allowed daily light 
and dark periods of 12 hours each. 
 
Drug Administration 
 Eight rats were euthanized at the time of loading to act as the baseline control group and a 
second 8 rats were euthanized 7 days post-loading as the ‘7 day’ loading control group. The 
remainder of the rats (n=96) commenced treatment with Vehicle (polyethylene glycol/ PEG; Peg 400: 
BHD chemical, BDH laboratory supplies, England) or the specific COX-2 inhibitor, DFU ([5,5-
dimethyl-3-3(3 fluorophenyl)-4-(4 methylsulphonal) phenyl-2 (5H)-furanone], Merck & Co., USA) 
suspended in PEG, at two doses (0.02mg/kg/ml and 2.0mg/kg/ml). Drug administration commenced 
7 days post-loading via intraperitoneal injection and continued daily until rats were euthanized by 
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CO2 inhalation at 14 days (T1), 21 days (T2), 28 days (T3) or 35 days (T4) post-loading. Refer to 
Table 1 for a summary of the treatment groups. 
 
For dynamic histomorphometry, two tetracycline labels, calcein (7mg.kg-1, 1%) (i.p.; Sigma 
Chemical Co, St Louis MO, USA) and alizarin complexone (20mg.kg-1, 1.5%) (i.p.; Sigma Chemical 
Co, St Louis MO, USA) were injected 8 and 3 days before sacrifice, respectively, to allow a 5 day 
interlabel period.  
 
Table 1: Summary of experimental groups based on loading and administration of the COX-2 
inhibitor DFU. 
Treatment group Post-Loading Period (days) 
Baseline control 0 
7-day (loaded) control 7 
Vehicle 
DFU[2.0mg/kg/ml] Timepoint 1 (T1) 
DFU[0.02mg/kg/ml]
14 
Vehicle 
DFU[2.0mg/kg/ml] Timepoint 2 (T2) 
DFU[0.02mg/kg/ml]
21 
Vehicle 
DFU[2.0mg/kg/ml] Timepoint 3 (T3) 
DFU[0.02mg/kg/ml]
28 
Vehicle 
DFU[2.0mg/kg/ml] Timepoint 4 (T4) 
DFU[0.02mg/kg/ml]
35 
  
Tissue Processing 
The unloaded left tibiae and loaded right tibiae were dissected and placed in separate vials of 
cold 10% neutral buffered formalin (NBF) and refrigerated immediately. The loading region in each 
tibia was defined as the 10mm zone, 4mm proximal to the tibiofibular junction and was isolated 
using a diamond wire saw (Precision Wire Saw: Alburg Technical Equipment Corporation, USA). 
The distal 5mm of this loading zone was fixed in cold NBF (10%), vacuumed overnight, infiltrated 
for a minimum of 1 week at 4°C, washed in 70% ethanol and embedded in polymethylmethacrylate 
(PMMA) to produce thick sections (>50µm) for the analysis of woven bone structural parameters.  
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Structural Histomorphometry 
 Thick transverse sections (70 – 100 µm) were cut from each PMMA block on a diamond-
blade microtome (Leitz 1600 Saw Microtome, Leica, Wetzlar). Each unstained section was mounted 
separately on glass slides and analyzed using light and fluorescence microscopy using an Olympus 
BX-60 Fluorescence microscope at a magnification of x10. The microscope was connected to a 
Macintosh computer via a digitizing tablet (Calcomp Drawing Slate, Calcomp Scottsdale, AZ) and 
used to transfer measured indices from a known-sized area of the microscope field to the computer. 
The following parameters were directly measured from each rat tibia (abbreviated according to Parfitt 
et al. [26]): periosteal woven bone perimeter (WoB.Pm); woven bone width (WoB.Wi); periosteal 
cortical perimeter (Ps.Ct.Pm); and endocortical perimeter (Ec.Pm). The program KSS Stereology 
(KSS, Salt Lake City) was used to calculate secondary variables required for the analysis of bone 
adaptation based on the parameters described by Li et al. [27], which included: absolute woven bone 
area (Ab.WoB.Ar); and absolute cortical area (Ct.Ar). Using these measured and calculated indices, 
bone remodeling indices were also calculated: percentage woven bone area (Ab.WoB.Ar/ Ct.Ar x 
100, %), percentage woven bone perimeter (WoB.Pm/ Ps.Ct.Pm x 100, %), woven bone apposition 
rate ([WoB.Wi + WoB.Pm]/[2 x treatment period in days], µm/d) and woven bone formation rate 
(WoB.App x WoB.Pm/ Ps.Ct.Pm, µm/d).  
 
Statistical Analysis 
All data was analyzed using StatView (version 5.0; SAS Institute Inc., Cary, North Carolina, 
USA, 1992-1999) using a two-way analysis of variance (ANOVA) and significant differences were 
determined post-hoc using Fisher’s PLSD. Significance was accepted at P < 0.05. Probability levels 
between 0.05 and 0.1 were classified as marginal if the difference between means was greater than 
twice the SEM and non-significant at P > 0.1. 
 
RESULTS 
Five rats were excluded from the woven bone analysis due to illness during the treatment 
period: one rat from the 7 day loaded control group; one rat treated with the high dose of DFU and 
sacrificed at T2 (21 days post-loading); one rat treated with the low dose of DFU and sacrificed at 
T3; and two rats treated with the high dose of DFU and sacrificed at T3 (28 days post-loading).  
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Characterization of Woven Bone 
Woven bone was easy to characterize at early stages of formation having extensive spaces 
around blood vessels and diffuse fluorochrome label [28] due to the rapid non-lamellar deposition of 
apatite crystals [29]. As the woven bone began to consolidate however, classification became more 
difficult as the morphology started to resemble that of lamellar bone and diffuse fluorochrome 
labeling was no longer present due to a decrease in formation activity. In these early stages of 
consolidation woven bone was characterized by rounded and irregularly aligned lacunae, whilst 
consolidated bone was characterized by relatively small and flat lacunae that usually were aligned in 
parallel rows [30]. 
 
Structural Histomorphometric Analysis 
Following a single episode of 4-point-bending in the rat, woven bone was laid down rapidly 
and preferentially on the lateral and anteromedial surfaces of the right tibial diaphysis. No woven 
bone was detected on the unloaded left tibial diaphysis. Seven days after the single loading event, 
percentage woven bone perimeter (%WoB.Pm), woven bone width (WoB.Wi), woven bone 
apposition rate (WoB.App) and woven bone formation rate (Wo.BFR) had all increased to a level 
significantly greater than baseline (P<0.05) in the distal diaphysis of the right rat tibia of Vehicle-
treated rats (VEH) (Table 2). An increase in percentage woven bone area (%WoB.Ar) was also 
observed but did not reach significance until 14 days (P<0.05) (Figure 1). There were no significant 
differences between VEH and DFU-treated rats up to 14 days post-loading. 
 
Woven bone apposition rate and woven bone formation rate decreased slowly in VEH rats 
after reaching a peak at 7 and 14 days, respectively, to return to basal levels at 28 and 21 days post-
loading, respectively. In rats treated with 2.0 mg/kg DFU, WoB.App and Wo.BFR decreased more 
rapidly than in VEH rats, returning these formation parameters to basal levels in the third week. This 
was followed by a significant rise in WoB.App and Wo.BFR at 28 and 35 days above baseline levels 
in DFU-treated rats (Table 2 and Figure 2). 
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Figure 1: The effect of 4-point-bending on Percentage Woven Bone Area (%WoB.Ar, %) in the tibia 
of rats treated with Vehicle and the COX-2 inhibitor, DFU, at two doses (0.02mg/kg/ml and 
2.0mg/kg/ml) at 14, 21, 28 and 35 days postloading. Values are the mean ± standard error of 8 rats. 
 
 
 
Figure 2: The effect of 4-point-bending on Woven Bone Formation Rate (Wo.BFR, µm/d) in the tibia 
of rats treated with Vehicle and the COX-2 inhibitor, DFU, at two doses (0.02mg/kg/ml and 
2.0mg/kg/ml) at 14, 21, 28 and 35 days postloading. Values are the mean ± standard error of 8 rats. 
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Percentage WoB.Pm reached a peak at the end of the third week, when 10.3% of the 
periosteal surface was lined with new woven bone. At the end of the 4th week, percentage WoB.Ar 
and WoB.Wi peaked at 2.6% and 45.75µm, respectively, in VEH rats. These peak values were 
comparable, and not statistically different, to those in DFU-treated rats, but were not observed in 
DFU-treated animals until 35 days post-loading. In the fifth week, woven bone perimeter, width and 
area had observable decreases only in VEH rats and only %WoB.Ar returned to basal levels by 35 
days post-loading following VEH treatment. Both doses of DFU were associated with significantly 
higher levels of %WoB.Ar at 35 days, but only rats treated with 2.0 mg/kg had significantly greater 
Wo.BFR at the final timepoint when compared to baseline (Figure 1 and 2). In contrast WoB.Wi and 
%WoB.Pm remained significantly elevated compared to baseline at the final timepoint for all rats 
(P<0.01).  
 
Differences between VEH and DFU treatment were largely seen in weeks 3 and 4, when 
DFU-treated rats were observed to have reduced woven bone parameters. At 21 days post-loading, 
rats treated with the higher dose of DFU had significantly lower %WoB.Ar and %WoB.Pm, and 
marginally lower WoB.Wi than VEH (P<0.05); and rats treated with the lower dose of DFU 
(0.02mg.kg-1) had significantly lower WoB.Wi. At 28 days, both DFU treatments were still 
associated with lower woven bone area, perimeter and width, but only rats treated with the lower 
dose of DFU had values that remained significantly lower than VEH (P<0.01).  
 
Periosteal cortical perimeter (Ct.Pm) and Ct.Ar were significantly greater than baseline at 28 
days in VEH rats (Table 3). Marginal increases in cortical area and perimeter were also seen with 
DFU treatment over the 5-week post-loading period but did not reach significance. Cortical perimeter 
in VEH rats returned to basal levels at 35 days post-loading, whilst Ct.Pm remained relatively higher 
than baseline in DFU-treated rats (P=0.057[0.02] & P=0.132[2.0]). 
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Table 2: The effect of the COX-2 inhibitor, DFU, on woven bone parameters in the rat tibia following a 
single episode of 4-point-bending. Values are mean (SEM) for percentage woven bone area (%WoB.Ar), 
percentage woven bone perimeter (%WoB.Pm), woven bone width (WoB.Wi), woven bone apposition 
rate (WoB.App) and woven bone formation rate (Wo.BFR) measured in the distal diaphysis of the rat 
tibia. Treatment commenced 7 days post-loading with Vehicle or the specific COX-2 inhibitor, DFU, at 
two doses: 0.02mg/kg/d and 2.0mg/kg/d. AP<0.05 vs baseline; BP<0.05 vs 7 day control; CP<0.05 vs VEH 
at the same timepoint; DP<0.08 vs 7d control; EP<0.08 vs VEH at the same timepoint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%WoB.Ar  
(%) 
%WoB.Pm 
(%) 
WoB.Wi  
(μm) 
WoB.App 
(μm/d) 
Wo.BFR  
(μm/d) 
7 day Control  0.55 (0.11)  6.25 (1.14)A  25.72 (6.13)A  3.63 (0.89)A  0.2 (0.04)A 
14 
days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
1.79 (0.78)A 
1.71 (0.56)A 
0.96 (0.46)A 
9.77 (3.11)A 
10.75 (2.88)A
4.87 (1.80)A 
33.47 (6.88)A 
32.29 (6.68)A 
29.00 (7.99)A 
2.39 (0.49)AD 
2.31 (0.48)AB 
2.07 (0.57)AB 
0.33 (0.15)A
0.32 (0.11)A
0.17 (0.08)A
21 
days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
2.07 (0.45)A 
1.13 (0.59) 
0.39 (0.25)C 
10.29 (1.90)A
6.67 (3.12)A 
2.19 (0.78)C 
44.61 (9.52)A 
23.08 (6.37)AC 
25.00 (8.74)AE 
2.16 (0.46)AB 
1.10 (0.30)BE 
1.25 (0.41)B 
0.23 (0.05)A
0.13 (0.07) 
0.04 (0.03)BE
28 
days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
2.60 (0.98)AB 
0.32 (0.12)C 
1.70 (0.42)AB 
9.09 (2.54)A 
2.49 (0.84)C 
9.49 (2.57)A 
45.75 (9.58)AD 
22.47 (5.87)AC 
44.53 (4.45)AD 
1.63 (0.34)AB 
0.80 (0.21)B 
1.59 (0.16)AB 
0.20 (0.07) 
0.03 (0.01)D 
0.14 (0.04)A
35 
days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
1.57 (0.68) 
2.69 (0.85)AB 
2.34 (0.47)AB 
7.48 (1.77)A 
9.57 (2.30)A 
10.21 (1.59)AD
35.22 (8.09)A 
43.57 (9.55)AD 
48.86 (5.78)AB 
1.01 (0.23)B 
1.25 (0.27)AB 
1.40 (0.17)AB 
0.10 (0.04) 
0.15 (0.05) 
0.16 (0.03)A
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Table 3: The effect of the COX-2 inhibitor, DFU, on woven and cortical bone parameters in the rat tibia 
following a single episode of 4-point-bending. Values are mean (SEM) for absolute woven bone area 
(Ab.WoB.Ar), cortical bone area (Ct.Ar) and periosteal cortical perimeter (Ps.Ct.Pm) measured in the 
distal diaphysis of the rat tibia. Treatment commenced 7 days post-loading with Vehicle or the specific 
COX-2 inhibitor, DFU, at two doses: 0.02mg/kg/d and 2.0mg/kg/d. AP<0.05 vs baseline; BP<0.05 vs 7 day 
control; CP<0.05 vs VEH at the same timepoint; EP<0.08 vs VEH at the same timepoint. 
 
 
 
 
 
 
 
  
 
 
Ab.WoB.Ar  
(x 104 μm2) 
Ct.Ar  
(x 106 μm2) 
Ps.Ct.Pm  
(μm) 
Baseline  0  4.31 (0.2894)  18348.76 (825.56) 
7 day Control  2.74 (0.6156)  4.39 (0.3425)  18102.47 (870.71) 
14 
days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
7.36 (3.0166) 
7.35 (2.5364)A 
4.54 (2.1862) 
4.47 (0.2123) 
4.44 (0.2124) 
4.21 (0.2666) 
18376.46 (985.57) 
17965.72 (932.04) 
16971.13 (1587.59) 
21 days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
8.63 (1.9807)A 
4.85 (2.4843) 
1.94 (1.1397)E 
4.21 (0.1384) 
4.48 (0.1063) 
4.72 (0.1521)E 
18099.44 (822.84) 
19073.68 (745.466) 
19900.72 (528.68) 
28 days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
12.68 (4.8280)AB 
1.55 (0.5934)C 
8.00 (2.0079)AB 
5.02 (0.1057)A 
4.76 (0.1635) 
4.66 (0.9150) 
21663.21 (645.76)AB 
19166.76 (1102.75) 
19541.46 (895.65) 
35 days 
Vehicle 
DFU[0.02] 
DFU[2.0] 
7.71 (3.2152) 
11.26 (3.7084)AB 
11.51 (2.4212)AB 
4.85 (0.1505) 
47.7 (0.1277) 
4.85 (0.1015) 
19891.65 (1231.41) 
20824.66 (976.88)B 
20699.43 (1384.98) 
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DISCUSSION 
WOVEN BONE FORMATION 
Vehicle Treatment 
 The rapid and significant increase in woven bone apposition rate during the first week 
following the single loading episode, suggests a rapid increase in the activity of osteoblasts 
immediately following the loading event, allowing for a rapid induction of woven bone formation. 
This is consistent with previous reports where mineral apposition rate peaks 5 to 8 days following 4-
point-loading in the rat tibia [31] and a period of rapid woven bone formation commences 5 to 7 days 
following mechanical stimulation in animal models [25, 32, 33]. After reaching peaks in the first and 
second weeks post-loading, woven bone apposition rate (WoB.App) and woven bone formation rate 
(Wo.BFR) returned to basal levels at 35 and 28 days, respectively. Therefore the loading-induced 
increase in osteoblast activity and woven bone formation was largely restricted to the first three 
weeks following the loading bout as reflected in the achievement of peak %WoB.Ar at 28 days, 
ending the period of loading-induced renewed modeling.  
 
COX-2 Inhibition  
Early studies demonstrated that woven bone formation is inhibited with Indomethacin 
treatment [9, 14, 34]. But, early woven bone formation was not affected by Indomethacin or NS-398 
treatment following loading [35] or cytokine stimulation [36] in more recent studies. This suggests 
that early woven bone formation may not be dependent on COX signaling and prostaglandin 
production.  
 
In agreement with Forwood [35], and Mackie and Trechsel [36], COX-2 inhibition did not 
prevent the formation of periosteal woven bone following loading. There was no significant 
difference in peak %WoB.Ar, peak %WoB.Pm or peak WoB.Wi between Vehicle-treated control 
(VEH) rats and those treated with either dose of DFU. Furthermore, there was no significant defect in 
the shape or size of the periosteal callus with DFU treatment. In contrast to the steady growth phase 
observed in VEH rats however, %WoB.Ar, %WoB.Pm and WoB.Wi did not increase progressively 
with DFU treatment after 7 days but rather were associated with a biphasic formation response. At 21 
days, only VEH rats had a significantly greater WoB apposition rate and Wo.BFR than baseline, 
indicating a decrease in formation activity with DFU treatment in the third week. This returned 
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woven bone formation to basal levels and significantly reduced woven bone parameters. It is possible 
that the retardation of woven bone formation induced by DFU caused premature consolidation of the 
woven bone callus, characterized by an early reduction of the woven bone callus and/or a 
transformation of woven bone into lamellar bone. This may explain the observed reduction in 
%WoB.Ar, %WoB.Pm and WoB.Wi at 21 days in rats treated with the higher dose of DFU.  
 
Based on the studies by Forwood [35] and Mackie and Trechsel [36], this significant decrease 
in woven bone formation with DFU treatment following loading was not expected. However 
treatments differed substantially between Forwood’s study and the present experiment. In the 
previous study, NS-398 was given as a single dose prior to loading and in the present study DFU was 
injected daily from the 7th day following loading. In cell cultures of human osteoblasts [37], DFU 
significantly reduces osteoblast number. But within 24 hours of its removal from the culture medium, 
cell numbers are seen to increase by 95%, suggesting that the adverse effects of DFU in reducing 
osteoblast numbers are reversible. Therefore in the study by Forwood [35], the single dose of NS-398 
prior to loading and/or the 5 to 8 day experimental period may not have been sufficient to observe 
any significant effect of the COX-2 inhibitor on woven bone formation. Osteoblast numbers may 
have normalized as woven bone formation progressed. This is also suggested by a partial, non-
significant, decrease in woven bone area following the single administration of NS-398, when 
compared to VEH in Forwood’s study [35]. 
 
Despite DFU treatment commencing 7 days post-loading, woven bone area in DFU-treated 
rats was not statistically different to VEH rats until 21 days when significant decreases were 
observed. Therefore, COX-2 inhibition appears to disrupt prolonged woven bone formation without 
significantly affecting the continued formation of woven bone in the second week post-loading. 
Bakker et al. [38] suggest that the anabolic response of bone to mechanical loading is dependent on 
COX-2-dependent prostaglandin release at the time of application of the loading bout. Since DFU 
treatment did not commence until 7 days post-loading, it is not surprising that the initial bone 
formation response was not perturbed. However two weeks after the commencement of DFU 
treatment, a severe retardation in woven bone modeling was observed. Evans et al. [37] report that in 
the presence of DFU, osteoblast numbers significantly decrease below control culture levels. This 
suggests that in the presence of DFU, continued woven bone formation may rely on continued 
osteoblastic activity alone in contrast to VEH rats which displayed maintenance of formation up to 21 
days post-loading suggesting ongoing recruitment of additional osteoblasts [31]. This was reflected in 
the significantly higher Wo.BFR in VEH rats at 21 days, in contrast to rats treated with the higher 
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dose of DFU. Hence the severe drop in woven bone formation in week 3 in DFU-treated rats 
exemplifies the importance of COX-2 in the amplification of PG biosynthesis required for prolonged 
osteoblast activity. 
 
In the 4th and 5th weeks, significant rises in woven bone parameters were observed in rats 
treated with DFU suggesting a late activation of osteoblastogenesis. Keller et al. [39] indicated that 
the role of prostaglandins is more important in the early stages of bone repair, having a limited 
physiological role in the later periods of fracture healing [11, 39-41]. The rapid rise in woven bone 
formation in the 4th and 5th weeks in DFU-treated rats may therefore reflect a period where continued 
woven bone formation relies on prostaglandin-independent pathways.   
 
Therefore the one week delay in the formation of peak WoB mass in DFU-treated rats did not 
occur through slower growth but rather an interruption in the phase of woven bone formation in the 
3rd week. These results agree with the endochondral bone fracture studies by Simon et al. [5] and 
Zhang et al. [6] that demonstrate delayed healing of the periosteal callus with Rofecoxib and 
Celecoxib treatment in rats and in COX-2-/- mice, respectively. These fracture studies have 
highlighted that COX-2 expression may be critical in cartilage-dependent bone formation [5, 6]. 
Therefore COX-2 inhibition causes a defect in woven bone adaptation that leads to delayed 
completion without significantly altering the gross structural development of the callus. With the 
observed delay in peak woven bone accrual in the current project and in the studies by Simon et al. 
[5] and Zhang et al. [6], COX-2 may have an important role in the augmentation of the woven bone 
response.  
 
WOVEN BONE CONSOLIDATION 
Vehicle Treatment 
Woven bone consolidation, or the conversion of woven bone into lamellar bone, was reflected 
in the significant increase in lamellar-like cortical bone area observed in VEH rats at 28 days post-
loading, coupled with decreases in %WoB.Pm and WoB.Wi, with %WoB.Ar returning to basal levels 
in the fifth week post-loading in VEH rats. Percentage woven bone perimeter and WoB.Wi however, 
remained significantly greater than baseline at T4, indicating that consolidation had not been fully 
completed by 35 days post-loading in VEH rats. 
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The mechanism of woven bone consolidation is still unclear. In the current study 
consolidation of woven bone progressed via two distinct mechanisms: (i) complete removal of woven 
bone elements via resorptive activity on the periosteal woven bone surface; and (ii) formation of 
lamellar bone within the peripheral/superficial zones of the woven bone callus, where the surface to 
volume ratio of woven bone appeared to determine the mechanism of consolidation implemented. 
During the consolidation process the latter mechanism dominated with much of the periosteal surface 
having a distinct bilayer morphology consisting of a superficial lamellar layer and a deep woven bone 
zone (Figure 3). This bilayer effect has also been described in studies by Kusuzaki et al. [30] in 
response to a femoral drill hole in rats, and by Rubin et al. [42] following osteotomy and a daily 
loading regime in turkey ulnae. Turner et al. [33] have proposed that the lamellar apposition onto the 
woven bone interface may act to compact and convert the woven bone into the more organized and 
dense lamellar construct. Woven bone compaction has been described by Enlow [43] during 
metaphyseal reduction in the growth of long bones. This emphasizes an important physiological 
relationship between the formation of woven and lamellar bone in response to mechanical loading. 
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Figure 3: Transverse sections of the rat tibia using Masson’s Trichrome stain, illustrating bilayer 
effect of consolidation between woven (arrows) and lamellar bone in both control and treated 
animals, 35 days postloading. Note the layer of lamellar bone lying superficial to the woven bone in 
both the top and bottom panels. 
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COX-2 Inhibitor (DFU) Treatment 
 Percentage woven bone perimeter and %WoB.Ar decreased significantly in DFU-treated rats 
between the 1st and 3rd weeks post-loading, suggesting an early onset of woven bone consolidation. 
This relationship was also observed during the final consolidation phase in VEH rats when decreases 
in perimeter preceded a significant fall in width. Therefore no difference in the mechanism of 
consolidation was observed between VEH and DFU-treated rats, despite temporal variants.  
 
 Early onset bone remodeling has been reported by Zhang et al. [6] in COX-2-/- mice following 
tibial fracture. Remodeling characteristic of the final stages of endochondral bone formation occurred 
7 days earlier in COX-2-/- mice than in wild-type mice. This suggests premature remodeling in 
response to defective woven bone formation in mice lacking COX-2 and supports the early phase of 
remodeling seen with DFU treatment following the 4-point-loading event. 
 
 Percentage woven bone area, %WoB.Pm, WoB.Wi, Wo.BFR and WoB apposition rate all 
remained significantly greater than baseline at 35 days post-loading, with the higher dose of DFU, in 
contrast to VEH in which %WoB.Ar, Wo.BFR and WoB apposition rate had all returned to baseline 
levels at the final timepoint. The elevated levels of Wo.BFR and WoB apposition rate at 35 days 
indicates that the DFU-treated rats were undergoing continued woven bone formation at the final 
timepoint and had not begun final consolidation. This resulted in a persistence of woven bone at 35 
days post-loading in DFU-treated rats, despite a significant reduction in the size of the periosteal 
woven bone callus and a marked decrease in formation activity in VEH rats.  
 
 In conclusion, treatment with a COX-2 inhibitor did not prevent the formation of the 
periosteal woven bone callus, nor retard the gross structural development of the periosteal woven 
bone callus following 4-point-bending of the tibia, such that there was no significant difference in 
peak woven bone area between DFU-treated and VEH rats. However treatment with the COX-2 
inhibitor resulted in a temporal defect in woven bone formation. The attainment of comparable peak 
woven bone parameters was delayed by one week in rats treated with the COX-2 inhibitor. Despite 
temporal differences, there was no observable difference in the mechanism of consolidation between 
VEH and DFU-treated rats, both operating predominately through a woven:lamellar bilayer 
mechanism. This suggests that COX-2 inhibition does not significantly disrupt woven bone 
remodeling, but rather alters its timing.  
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 It is hypothesized that the unusual biphasic woven bone formation response associated with 
COX-2 inhibitor treatment is of high significance, marking a period where COX-2 expression is 
especially important in woven bone modeling and when COX-2 inhibitors induce the most severe 
defects.  
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